This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Allergan Reports Second Quarter 2013 Operating Results

Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended June 30, 2013. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 12, 2013 to stockholders of record on August 22, 2013. As a result of Allergan’s approved plan to sell its obesity intervention business unit, the financial results from that business unit are reported as discontinued operations in the financial tables of this press release. Prior year amounts have been retrospectively revised for the discontinued operations.

Operating Results Attributable to Stockholders from Continuing Operations

For the quarter ended June 30, 2013:

  • Allergan reported $1.17 diluted earnings per share attributable to stockholders compared to $0.96 diluted earnings per share attributable to stockholders for the second quarter of 2012.
  • Allergan reported $1.22 non-GAAP diluted earnings per share attributable to stockholders compared to $1.05 non-GAAP diluted earnings per share attributable to stockholders for the second quarter of 2012, a 16.2 percent increase.

Product Sales from Continuing Operations

For the quarter ended June 30, 2013:

  • Allergan reported $1,577.0 million total product net sales. Total product net sales increased 10.6 percent compared to total product net sales in the second quarter of 2012. On a constant currency basis, total product net sales increased 10.9 percent compared to total product net sales in the second quarter of 2012.
    • Total specialty pharmaceuticals net sales increased 11.1 percent, or 11.5 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2012.
    • Total medical devices net sales increased 7.4 percent, or 7.7 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2012.

“In the second quarter, double digit sales and earnings growth is in line with our long term growth aspirations,” said David E.I. Pyott, Allergan’s Chairman of the Board and Chief Executive Officer. “We are also pleased with further R&D progress with the FDA Advisory Committee’s unanimous recommendation for JUVÉDERM VOLUMA™ XC and with the filing of OZURDEX® for diabetic macular edema in both the United States and Europe.”

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,096.52 +58.55 0.32%
S&P 500 2,112.25 +3.33 0.16%
NASDAQ 5,064.5860 +4.34 0.09%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs